在晚期黑色素瘤中选择一线免疫疗法:目前关于不同患者群体疗效的证据
Sophia Kreft1, Tommaso Bosetti1, Rebecca Lee1,2
1The Christie NHS Foundation Trust, Manchester, United Kingdom.
EJC skin cancer
|January 19, 2026
概括
尼沃卢马布-雷拉特利马布为晚期黑色素瘤提供了一种新的免疫疗法选择,比其他治疗方法显示出更好的疗效和更少的副作用. 需要进一步的数据来确定与现有疗法相比,其最佳使用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 免疫疗法彻底改变了晚期黑色素瘤的治疗方法,改善了生存率.
- 尼沃卢马布-雷拉利马布是一种新的一线免疫疗法选择.
- 它的长期疗效和直接比较数据有限.
研究的目的:
- 审查目前先进黑色素瘤的第一线免疫疗法的疗效.
- 为了指导临床决策选择最好的免疫疗法选项.
- 确定从特定治疗中受益最多的患者子组.
主要方法:
- 对单剂抗PD-1,nivolumab-relatlimab和ipilimumab-nivolumab的可用疗效数据的审查.
- 对不同患者群体治疗结果的分析.
- 基于疗效和毒性概况的临床定位的讨论.
主要成果:
- 尼沃卢马布-relatlimab 显示出比单剂尼沃卢马布更大的疗效,副作用比 ipilimumab-nivolumab 更少.
- 大多数对伊皮利穆马布-尼沃卢马布有反应的患者也对尼沃卢马布-雷拉利穆马布或抗PD-1单一疗法有反应.
- 由于长期数据有限,对尼沃卢马布-雷拉特利马布的最佳配置仍然存在不确定性.
结论:
- 尼沃卢马布-雷拉特利马布是第一线晚期黑色素瘤治疗的有效补充.
- 识别那些需要依皮利穆马布-尼沃卢穆马布而不是更少毒性选择的患者至关重要.
- 需要进一步的研究来建立这些免疫疗法的最终临床指南.
相关概念视频
05:33Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
2.3K
Here, we present a protocol to generate melanoma patient-derived organoids by culturing disassociated cell suspensions from fresh melanoma tissues. These organoids faithfully recapitulate patient-specific tumors in vitro, offering an innovative approach to exploring tumor immunosuppressive mechanisms, drug screening, drug resistance mechanisms, and cancer surveillance approaches.
2.3K
07:07A Melanoma Patient-Derived Xenograft Model
13.1K
Patient-derived xenograft (PDX) models more robustly recapitulate melanoma molecular and biological features and are more predictive of therapy response compared to traditional plastic tissue culture-based assays. Here we describe our standard operating protocol for the establishment of new PDX models and the characterization/experimentation of existing PDX...
13.1K
02:55The Evidence for Evolution
47.6K
Genetic variations accumulating within populations over generations give rise to biological evolution. Evolutionary changes can result in the formation of novel varieties and entire new species. These changes are responsible for the diverse forms of life inhabiting the planet. The evidence for evolution suggests that all living organisms descended from common ancestors.
47.6K
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
3.9K
The protocol presents a cancer immunotherapy model using cell-based tumor vaccination with Flt3L-expressing B16-F10 melanoma. This protocol demonstrates the procedures, including preparation of cultured tumor cells, tumor implantation, cell irradiation, measurement of tumor growth, isolation of intratumoral immune cells, and flow cytometry...
3.9K
09:38Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity
924
This protocol presents a step-by-step guide for performing minimally invasive isolated limb perfusion (MI-ILP), a treatment option for patients with locally advanced melanomas and sarcomas of the...
924
06:25Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
1.5K
This article describes a protocol for the propagation of cerebral spinal fluid-circulating tumor cells (CSF-CTCs) collected from patients with melanoma-associated leptomeningeal disease (M-LMD) to develop preclinical models to study...
1.5K